Skip to content

The effect of bupivacaine liposome ultrasound-guided intercostal nerve block on chronic postsurgical pain in patients with VATS: a prospective, two-centre, randomised controlled clinical trial

The effect of bupivacaine liposome ultrasound-guided intercostal nerve block on chronic postsurgical pain in patients with VATS: a prospective, two-centre, randomised controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089383
Enrollment
Unknown
Registered
2024-09-06
Start date
2024-09-09
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic postsurgical pain

Interventions

Experimental group:Postoperative analgesic use: bupivacaine liposomal ultrasound-guided T4-T9 multipoint intercostal nerve block + PCIA
Control group:Postoperative analgesia: PCIA alone

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) patients undergoing elective three-port thoracoscopic thoracic surgery (including lobectomy, segmental resection, and wedge resection of pulmonary nodules), (2) aged 18-75 years, and (3) American Society of Anaesthesiologists (ASA) classification I-III.

Exclusion criteria

Exclusion criteria: (1) emergency trauma surgery, (2) New York Heart Function Score (NYHA) 3-4, (3) conduction block, (4) unstable coronary artery disease, (5) gastric ulcers or gastric haemorrhage, (6) a body mass index (BMI) of 37 kg/m2, (7) diabetes mellitus treated with insulin, (8) renal insufficiency (serum creatinine value above the normal threshold), (9) hepatic insufficiency (alanine aminotransferase or aspartate aminotransferase more than twice normal), (10) coagulation disorders (prothrombin time or activated partial thromboplastin time higher than normal thresholds) or oral anticoagulants (warfarin, newer anticoagulants such as rivaroxaban, or dabigatran, among others) for other medical reasons, (11) alcohol or opioid abuse in the last 2 months. (12) Uncontrolled anxiety, schizophrenia and other psychiatric disorders, or inability to cooperate with follow-up visits or telephone calls (13) Pregnancy or pregnancy preparation, (14) History of allergy to local anaesthetics or any experimental drugs, (15) History of thoracic surgery, (16) Intraoperative mid-operative open chest, (17) Distant metastases at the time of diagnosis.

Design outcomes

Primary

MeasureTime frame
chronic postsurgical pain;

Secondary

MeasureTime frame
chronic postsurgical pain;Pain within 3 days after surgery;Quality of recovery 24 hours after surgery;Sleep quality 24 hours after surgery;First rescue analgesia time;First time out of bed;Incidence of postoperative nausea and vomiting;Incidence of postoperative pulmonary complications;Total length of hospital stay;Hospitalisation costs;

Countries

China

Contacts

Public ContactXiaoqiang Li

West China Hospital, Sichuan University

39006900@qq.com+86 189 8060 1475

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026